Bavarian Nordic is tackling some of the world’s toughest diseases

Our Portfolio

We have a growing portfolio aimed at addressing the unmet needs of infectious diseases and other emerging diseases. We’re focused on developing and delivering vaccines across these areas:


Smallpox and Ebola*

Safeguarding the population against biosecurity  threats and outbreaks

Rabies, TBE & Monkeypox

Protection at home and abroad 


Advancing new vaccine technologies to address unmet medical need


Advancing the development of a next-generation vaccine


Grey box indicates products in development, not yet approved.
RSV, Respiratory Syncytial Virus; TBE, tick-borne encephalitis.
*in collaboration with Janssen


Our History

Founded in 1994, Bavarian Nordic is committed to protecting the population against life-threatening diseases, through the development and manufacturing of innovative life-saving vaccine technologies.


Some of Our Key Milestones…


We have collaborated with the US government for nearly 20 years, applying our innovative vaccine platform technology to support and protect US citizens from biosecurity threats and outbreaks. We have also successfully partnered with Janssen on an approved Ebola vaccine.

Whilst proud of our achievements in vaccine development over the past 25 years, we are focused on the future. Right now, we are working on bringing patients around the globe an even greater degree of protection from infectious diseases.



We aspire to save and improve lives by unlocking the power of the immune system. Immunisation positively impacts, directly or indirectly, 14 of the 17 United Nations Sustainable Development Goals (SDGs) that support the 2030 Agenda for Sustainable Development. We are committed to growing responsibly whilst simultaneously supporting the of ensuring healthy lives and fostering innovation.  

Our focus is always on the patient which is why we continue to provide prescribers and healthcare professionals with support for medical and disease education to help improve awareness.    

With our recent acquisition of well-known and trusted vaccine products for rabies and tick-borne encephalitis from GSK, we are committed to expanding into new disease areas, and advancing the field of infectious diseases, such as COVID-19 and respiratory syncytial virus, through new vaccine technologies. 


Our Vision

Bavarian Nordic’s Chief Medical Officer, Laurence De Moerlooze, talks about our vision for prevention of infectious disease and what this means for healthcare professionals.

Laurence DeMoerlooze


Our Commitment to the Prevention of Infectious Diseases


Focus on COVID-19

We initiated a Phase 2 clinical trial of our next generation COVID-19 booster vaccine using capsid virus like particle (cVLP) technology. We are also preparing to conduct a Phase III trial of the vaccine in 2022

Providing Better Service

We are dedicated to building strong relationships with healthcare professionals and delivering customer-centric service

Vaccine Supply

Bavarian Nordic is a trusted vaccine supplier with end-to-end vaccine manufacturing capabilities

Patient Education

We have an educational site on infectious diseases to provide information and prevention measures for TBE.